Dore GJ - Search Results

1

Adherence to response-guided pegylated interferon and ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: the ACTIVATE study.

Cunningham EB, Hajarizadeh B, Dalgard O, Amin J, Hellard M, Foster GR, Bruggmann P, Conway B, Backmund M, Robaeys G, Swan T, Marks PS, Quiene S, Applegate TL, Weltman M, Shaw D, Dunlop A, Bruneau J, Midgard H, Bourgeois S, Thurnheer MC, Dore GJ, Grebely J; ACTIVATE Study Group. Cunningham EB, et al. Among authors: dore gj. BMC Infect Dis. 2017 Jun 13;17(1):420. doi: 10.1186/s12879-017-2517-3. BMC Infect Dis. 2017. PMID: 28610605 Free PMC article. Clinical Trial.

2

Dual efficacy of lamivudine treatment in human immunodeficiency virus/hepatitis B virus-coinfected persons in a randomized, controlled study (CAESAR). The CAESAR Coordinating Committee.

Dore GJ, Cooper DA, Barrett C, Goh LE, Thakrar B, Atkins M. Dore GJ, et al. J Infect Dis. 1999 Sep;180(3):607-13. doi: 10.1086/314942. J Infect Dis. 1999. PMID: 10438346 Clinical Trial.

3

Risk factors leading to Cryptosporidium infection in men who have sex with men.

Hellard M, Hocking J, Willis J, Dore G, Fairley C. Hellard M, et al. Sex Transm Infect. 2003 Oct;79(5):412-4. doi: 10.1136/sti.79.5.412. Sex Transm Infect. 2003. PMID: 14573839 Free PMC article.

4

Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients coinfected with HIV-1 and hepatitis B virus.

Dore GJ, Cooper DA, Pozniak AL, DeJesus E, Zhong L, Miller MD, Lu B, Cheng AK; 903 Study Team; 907 Study Team. Dore GJ, et al. J Infect Dis. 2004 Apr 1;189(7):1185-92. doi: 10.1086/380398. Epub 2004 Mar 12. J Infect Dis. 2004. PMID: 15031786 Clinical Trial.

5

HIV and hepatitis C coinfection within the CAESAR study.

Amin J, Kaye M, Skidmore S, Pillay D, Cooper DA, Dore GJ. Amin J, et al. Among authors: dore gj. HIV Med. 2004 May;5(3):174-9. doi: 10.1111/j.1468-1293.2004.00207.x. HIV Med. 2004. PMID: 15139984 Free article. Clinical Trial.

6

Clearance of hepatitis C virus after newly acquired infection in injection drug users.

Jauncey M, Micallef JM, Gilmour S, Amin J, White PA, Rawlinson W, Kaldor JM, van Beek I, Dore GJ. Jauncey M, et al. Among authors: dore gj. J Infect Dis. 2004 Oct 1;190(7):1270-4. doi: 10.1086/423943. Epub 2004 Aug 18. J Infect Dis. 2004. PMID: 15346337

7

Hepatitis C virus incidence among injecting drug users on opioid replacement therapy.

Hallinan R, Byrne A, Amin J, Dore GJ. Hallinan R, et al. Among authors: dore gj. Aust N Z J Public Health. 2004 Dec;28(6):576-8. doi: 10.1111/j.1467-842x.2004.tb00050.x. Aust N Z J Public Health. 2004. PMID: 15707209 Free article.

8

Treatment for hepatitis C virus infection among current injection drug users in Australia.

Matthews G, Kronborg IJ, Dore GJ. Matthews G, et al. Among authors: dore gj. Clin Infect Dis. 2005 Apr 15;40 Suppl 5:S325-9. doi: 10.1086/427448. Clin Infect Dis. 2005. PMID: 15768342 Review.

9

Hepatitis C virus prevalence and outcomes among injecting drug users on opioid replacement therapy.

Hallinan R, Byrne A, Amin J, Dore GJ. Hallinan R, et al. Among authors: dore gj. J Gastroenterol Hepatol. 2005 Jul;20(7):1082-6. doi: 10.1111/j.1440-1746.2005.03882.x. J Gastroenterol Hepatol. 2005. PMID: 15955218

10

Cancer incidence in people with hepatitis B or C infection: a large community-based linkage study.

Amin J, Dore GJ, O'Connell DL, Bartlett M, Tracey E, Kaldor JM, Law MG. Amin J, et al. Among authors: dore gj. J Hepatol. 2006 Aug;45(2):197-203. doi: 10.1016/j.jhep.2006.02.014. Epub 2006 Mar 31. J Hepatol. 2006. PMID: 16684579

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

528 results

Search Page

Filters